President Donald Trump on Oct. 10 announced an agreement with AstraZeneca to lower drug prices in the U.S.
The deal includes U.K.-based AstraZeneca selling medications to Medicaid at “most-favored-nation” prices. The company will also offer many popular drugs directly to consumers at discounted rates through a federal website, TrumpRx.gov, which is expected to launch in 2026.
“The lowest price anywhere in the world, that’s what we get,” President Trump said. “A move that will save American taxpayers hundreds of millions of dollars each year.”
Under the agreement, AstraZeneca also committed to applying the most-favored-nation pricing model to all future medications brought to market in the U.S. The company will also invest $50 billion into U.S.-based manufacturing and research and development operations.
President Trump revived the “most-favored-nation” policy by executive order in May. A previous version of the policy during his first term was blocked by a federal judge due to regulatory issues.
This deal follows a similar agreement last month between the Trump administration and New York City-based Pfizer. CMS Administrator Mehmet Oz, MD, who also spoke at the briefing, said there are more deals with drugmakers in the pipeline.
“By the time this [presidential] term is done, 95% of all drugs sold in America — branded drugs and generic — will be available at most favored nation pricing,” Dr. Oz said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
